viewSynairgen PLC

Synairgen focuses on chronic obstructive pulmonary disease candidate supporting coronavirus programme


  • Focused on respiratory disease
  • Two drug candidates, one developed in-house, one by a partner
  • Lead candidate tested for coronavirus
lung x-ray

Quick facts: Synairgen PLC

Price: 177 GBX

Market: AIM
Market Cap: £292.21 m

The lead candidate

Synairgen plc's (LON:SNG) lead candidate is SNG001, an inhaled interferon beta drug designed for people with chronic obstructive pulmonary disease (COPD) who are also suffering cold or flu infections.

In September it submitted a patent application, 

The application follows the results of interim analysis of Synairgen’s exploratory Phase II clinical trial of SNG001 in COPD patients, which revealed that the treatment is well tolerated in the older population studied and that lung antiviral responses were “significantly enhanced”.

The patent submission follows a similar application by Synairgen in July for the use of inhaled interferon beta in COVID-19 patients.

The company is in discussions with “a number of regulatory agencies worldwide” to establish a route to the approval for its drug as a treatment of the severe symptoms of the virus and is working closely with its manufacturing partners on “scale-up activity”.


Synairgen’s BioBank

Over the years, Synairgen has accumulated an extensive bank comprised of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma or COPD. Using this resource, the company has developed a number of advanced tissue models.

It uses these models to:

  • Discover novel drug targets
  • Identify disease-related lesions and underlying molecular mechanisms
  • Conduct proof of concept testing and validation of novel drug targets
  • Conduct screening assays for novel drug targets and lead target selection
  • Provide support for clinical trial activities


What the boss says: Richard Marsden, chief executive

"We are very pleased to have generated patentable findings for our wholly-owned inhaled interferon beta candidate, SNG001, in both COPD and COVID-19 patients.”

“Whilst recognising that the COPD trial data provide a strong rationale for assessing SNG001 in COPD patients with severe viral lung infections, our immediate priority is to progress SNG001 as a therapeutic for COVID-19. Together with our advisors we are working to protect the value of this drug for shareholders and commercial partners over the longer term."



Inflexion points 

  • Results from COVID-19 trial
  • Partner for NASH candidate
  • COPD patent submitted


What the broker says

finnCap holds a target price of 360p, though analysts said quantifying the coronavirus opportunity was “nigh on impossible” as the valuation “could go substantially higher”.

What happens next will depend on the “upcoming discussions with regulators, which should clarify the route to market and the potential for buying SNG001 ahead of the winter 2020 flu season and the possibility of a second wave of COVID-19”.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...


Synairgen plans after £80m share sale to fund crucial trial of breakthrough...

Synairgen PLC's Richard Marsden (LON:SNG) talks to Proactive London's Katie Pilbeam about the £80m share placing to finance its lead drug through final-stage clinical trials in patients with severe coronavirus (COVID-19). Marsden explains the reason behind involving 900 patients in 20...

3 days, 6 hours ago

2 min read